Building on proprietary world class high sensitivity arrhythmia and respiratory algorithms and software developed in collaboration with research and clinical partners, the company has created a robust technology platform that is increasingly being used to improve patient care, reduce diagnosis times, provide re-assurance to patients and help deliver significant healthcare savings.
Nurturing our core vision of increasing the accessibility of great healthcare and improving patient safety, our products are unobtrusive for patients, intuitive for nurses and effortless for clinicians. Enhancing patient monitoring and intervention in hospital and home environments potentially reduces the need for hospital beds and outpatient visits.
With a legacy embedded within the Ulster University, we retain a close working relationship with the Nanotechnology and Integrated BioEngineering Centre (NIBEC) enabling access to world class academia. This relationship has further allowed us to recruit a team of engineers, whose expertise and talent, has driven our product development.
Full regulatory approval for our product range has been achieved in both the EU and USA and our technology is currently deployed in multiple international markets.